Catalyst Pharmaceutical Partners is a development-stage specialty pharmaceutical company engaged in developing and commercializing prescription drugs that target orphan drug diseases as well as disorders of the central nervous system. The company currently has three products in development: Firdapse, planned for development to treat Lambert-Eaton Myasthenic Syndrome (LEMS); CPP-115, planned to be developed for treating epilepsy; and CPP-109, intended to be developed as a treatment for Tourette’s Disorder. For more information, visit the company’s Web site at www.catalystpharma.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: